Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, Tsionos K, Bamias A, Meletis J, Dimopoulos MA, Terpos E. Anagnostopoulos A, et al. Among authors: tsionos k. Br J Haematol. 2007 Jun;137(6):560-8. doi: 10.1111/j.1365-2141.2007.06609.x. Br J Haematol. 2007. PMID: 17451406 Free article.
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K, Panayiotidis P, Dimopoulos MA, Pangalis GA, Kyrtsonis MC; Greek Myeloma Study Group. Anargyrou K, et al. Among authors: tsionos k. Haematologica. 2008 Mar;93(3):451-4. doi: 10.3324/haematol.11852. Epub 2008 Feb 20. Haematologica. 2008. PMID: 18287135 Free article.
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D, Pouli A, Michalis E, Delimpasi S, Gkotzamanidou M, Nikitas N, Koumoustiotis V, Margaritis D, Tsionos K, Stefanoudaki E, Meletis J, Zervas K, Dimopoulos MA; Greek Myeloma Study Group, Greece. Terpos E, et al. Among authors: tsionos k. Int J Cancer. 2012 Feb 1;130(3):735-42. doi: 10.1002/ijc.26062. Epub 2011 May 30. Int J Cancer. 2012. PMID: 21484787 Free article.
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA. Terpos E, et al. Among authors: tsionos k. Leukemia. 2008 Dec;22(12):2247-56. doi: 10.1038/leu.2008.235. Epub 2008 Sep 4. Leukemia. 2008. PMID: 18769451 Clinical Trial.
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group. Terpos E, et al. Among authors: tsionos k. Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638. Haematologica. 2009. PMID: 19252175 Free PMC article. Clinical Trial.
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL).
Boutsikas G, Terpos E, Markopoulos A, Papatheodorou A, Stefanou A, Georgiou G, Galani Z, Komninaka V, Telonis V, Anagnostopoulos I, Dimitrakopoulou L, Anargyrou K, Tsionos K, Christoulas D, Gonianaki M, Giannikos T, Kokoris S, Konstantopoulos K, Meletis J, Angelopoulou MK, Travlou A, Vassilakopoulos TP. Boutsikas G, et al. Among authors: tsionos k. J BUON. 2017 Jul-Aug;22(4):1022-1031. J BUON. 2017. PMID: 28952223 Free article.
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.
Anargyrou K, Fotiou D, Vassilakopoulos TP, Christoulas D, Makras P, Dimou M, Ntanasis-Stathopoulos I, Masouridou S, Angelopoulou MK, Papatheodorou A, Tsionos K, Panayiotidis P, Dimopoulos MA, Terpos E. Anargyrou K, et al. Among authors: tsionos k. Hemasphere. 2019 Sep 24;3(6):e303. doi: 10.1097/HS9.0000000000000303. eCollection 2019 Dec. Hemasphere. 2019. PMID: 31976477 Free PMC article.
16 results